<code id='535FBA5CB0'></code><style id='535FBA5CB0'></style>
    • <acronym id='535FBA5CB0'></acronym>
      <center id='535FBA5CB0'><center id='535FBA5CB0'><tfoot id='535FBA5CB0'></tfoot></center><abbr id='535FBA5CB0'><dir id='535FBA5CB0'><tfoot id='535FBA5CB0'></tfoot><noframes id='535FBA5CB0'>

    • <optgroup id='535FBA5CB0'><strike id='535FBA5CB0'><sup id='535FBA5CB0'></sup></strike><code id='535FBA5CB0'></code></optgroup>
        1. <b id='535FBA5CB0'><label id='535FBA5CB0'><select id='535FBA5CB0'><dt id='535FBA5CB0'><span id='535FBA5CB0'></span></dt></select></label></b><u id='535FBA5CB0'></u>
          <i id='535FBA5CB0'><strike id='535FBA5CB0'><tt id='535FBA5CB0'><pre id='535FBA5CB0'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:hotspot    Page View:39
          A person reaching for a bottle of lipitor. -- first opinion coverage from STAT
          John Moore/Getty Images

          The antibiotics crisis is a silent pandemic that threatens to knock modern society back into the medieval age of therapeutic leaches and serum therapy. A world where an accidental scratch in the rose garden can kill.

          Why is the supply of new antibiotics so thin, and growing thinner? A high-profile Wall Street Journal article recently highlighted what everyone knows: There is huge need but no market demand.

          advertisement

          There are many interrelated causes. Doctors prefer to keep novel antibiotics in reserve, as a last-resort option, limiting sales volumes. Insurance companies like novel antibiotics that prevent costly ICU stays, but they’re used to the cheap price of older generics and balk at any price that allows recoupment of the full cost of development. Low prices and small volumes are a great recipe for insolvency as Achaogen’s experience showed.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more
          Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage
          Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

          INAFASSBENDER/AFPviaGettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup tog

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          Medicare Advantage enrollment grows 7.1% to 33.4 million people

          PabloMartinezMonsivais/APRoughly33.4millionadultsolderthan65andpeoplewithdisabilitieswereenrolledina